WO1998043649A3 - Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6? - Google Patents

Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6? Download PDF

Info

Publication number
WO1998043649A3
WO1998043649A3 PCT/JP1998/001365 JP9801365W WO9843649A3 WO 1998043649 A3 WO1998043649 A3 WO 1998043649A3 JP 9801365 W JP9801365 W JP 9801365W WO 9843649 A3 WO9843649 A3 WO 9843649A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
maillard reaction
reaction inhibitor
production inhibitory
inhibitory composition
Prior art date
Application number
PCT/JP1998/001365
Other languages
French (fr)
Other versions
WO1998043649A2 (en
Inventor
Koichi Yasumura
Shintaro Ishikawa
Tadami Utsunomiya
Kazuhiko Hayashi
Tadashi Okada
Original Assignee
Otsuka Pharma Co Ltd
Koichi Yasumura
Shintaro Ishikawa
Tadami Utsunomiya
Kazuhiko Hayashi
Tadashi Okada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Koichi Yasumura, Shintaro Ishikawa, Tadami Utsunomiya, Kazuhiko Hayashi, Tadashi Okada filed Critical Otsuka Pharma Co Ltd
Priority to AU65185/98A priority Critical patent/AU6518598A/en
Publication of WO1998043649A2 publication Critical patent/WO1998043649A2/en
Publication of WO1998043649A3 publication Critical patent/WO1998043649A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Abstract

An AGE production inhibitor composition which inhibits the production of an AGE, causative of diabetic complications such as cataract, nephropathy, and retinopathy, is provided. The composition comprises (a) a Maillard reaction inhibitor, e.g., a compound represented by formula (1), (2) or (3), or a pharmaceutically acceptable salt thereof, and (b) vitamin B6 or a pharmaceutically acceptable salt thereof, wherein the individual groups are as described in the specification.
PCT/JP1998/001365 1997-03-28 1998-03-26 Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6? WO1998043649A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65185/98A AU6518598A (en) 1997-03-28 1998-03-26 Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b6

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7860197 1997-03-28
JP9/78601 1997-03-28

Publications (2)

Publication Number Publication Date
WO1998043649A2 WO1998043649A2 (en) 1998-10-08
WO1998043649A3 true WO1998043649A3 (en) 1998-12-17

Family

ID=13666431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/001365 WO1998043649A2 (en) 1997-03-28 1998-03-26 Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?

Country Status (3)

Country Link
AR (1) AR012199A1 (en)
AU (1) AU6518598A (en)
WO (1) WO1998043649A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071298B2 (en) 1997-02-05 2006-07-04 Fox Chase Cancer Center Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins
WO2000024405A1 (en) * 1998-10-28 2000-05-04 Fox Chase Cancer Center Compounds and their therapeutic use with diabetic complications
HRP20000410B1 (en) * 2000-06-16 2012-06-30 Ba�i� Robert New inhibitor of apoptosis of nerve cells
DE60231833D1 (en) 2001-07-31 2009-05-14 Univ Wayne State HYBRID PROTEINS FACED WITH HEPARANSULFATE PROTEOGLYCANE WITH NEUREGULIN-HEPARIN BINDING DOMAIN
ES2275218T3 (en) 2003-05-07 2007-06-01 Osteologix A/S HYDROSOLUBLE STRONTIUM SALTS FOR THE TREATMENT OF CARTILAGOS AND / OR BONE AFFECTIONS.
SG173639A1 (en) 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002216A1 (en) * 1990-08-01 1992-02-20 Univ Rockefeller Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
WO1992014456A1 (en) * 1991-02-22 1992-09-03 Shapiro Howard K Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
EP0531812A1 (en) * 1991-08-27 1993-03-17 Otsuka Pharmaceutical Co., Ltd. Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof
US5272165A (en) * 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
WO1994019335A1 (en) * 1993-02-26 1994-09-01 Otsuka Pharmaceutical Co., Ltd. Thiazole or imidazole derivatives as maillard reaction inhibitors
WO1997009981A1 (en) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272165A (en) * 1984-03-19 1993-12-21 The Rockefeller University 2-alkylidene-aminoguanidines and methods of use therefor
WO1992002216A1 (en) * 1990-08-01 1992-02-20 Univ Rockefeller Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
WO1992014456A1 (en) * 1991-02-22 1992-09-03 Shapiro Howard K Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
EP0531812A1 (en) * 1991-08-27 1993-03-17 Otsuka Pharmaceutical Co., Ltd. Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof
WO1994019335A1 (en) * 1993-02-26 1994-09-01 Otsuka Pharmaceutical Co., Ltd. Thiazole or imidazole derivatives as maillard reaction inhibitors
WO1997009981A1 (en) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOOTH ET AL: "In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs). Novel Inhibition of Post-Amadori Glycation Pathways", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 9, 28 February 1997 (1997-02-28), pages 5430 - 5437, XP002068236 *
KHATAMI: "Inhibition of Nonenzymatic Glycolysation by Pyridoxal, Pyridoxal Phosphate and Aminoguanidine, a Potential Antivitamin B6 Agent", CURRENT STATUS OF PREVENTION AND TREATMENT OF DIABETIC COMPLICATIONS: PROCEEDINGS OF THE 3RD INTERNATIONAL SYMPOSIUM ON TREATMENT OF DIABETES MELLITUS, 13 July 1988 (1988-07-13) - 15 July 1988 (1988-07-15), pages 649 - 654, XP002068235 *
NAKAMURA ET AL: "A Novel AGE-Inhibitor Prevents the Progression of Diabetic Nephropathy in Otsuka-Long-Evans-Tokushima-Fatty Rat", JASN, vol. 7, no. 9, 1996, pages 1875, XP002079422 *

Also Published As

Publication number Publication date
AU6518598A (en) 1998-10-22
AR012199A1 (en) 2000-09-27
WO1998043649A2 (en) 1998-10-08

Similar Documents

Publication Publication Date Title
CA2273841A1 (en) 3-thiocarbamoylpyrazole derivatives as pesticides
WO2001072728A3 (en) Novel piperazine derivatives
CA2274464A1 (en) Ketobenzamides as calpain inhibitors
CA2385130A1 (en) Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
WO2005041653A3 (en) Synergistic fungicidal active combinations
EP0630898A4 (en) Thrombocytopenia remedy.
WO2003037864A1 (en) Indole compound and medicinal use thereof
NO20075066L (en) Pharmaceutical composition containing isoflavones
CA2265767A1 (en) Stable pharmaceutical composition including 4,5-epoxy-morphinan derivative
WO2001074774A1 (en) Ethylenediamine derivatives
HK1071510A1 (en) Acetylene derivatives having mglur 5 antagonistic activity
WO2001090071A3 (en) Substituted iminoazines used as herbicides
AU2231797A (en) Novel iridoid derivatives and a vascularization inhibitor having for its active ingredient said derivative
AU674378B2 (en) Use of 2-amino-6-A-propylamino-4,5,6, 7-tetrahydrobenzothiazole (pramipexol) as an anti-depressantdrug
WO2002102787A3 (en) Novel sulfonic acid derivatives
WO2003017760A3 (en) Fungicide active substance combinations
CA2470809A1 (en) 6-amino-morphinan derivatives, method of manufacturing them and their application
WO2002032901A3 (en) Bridged piperazine derivatives
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
EP0832875A4 (en) Highly water-soluble metalloproteinase inhibitor
CA2200126A1 (en) Treatment and prophylaxis of pancreatitis
WO1998043649A3 (en) Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
WO2000046210A3 (en) New process for preparing pesticidal intermediates
WO2001066527A8 (en) Substituted benzoylcyclohexenones
EP1008345A4 (en) Antiallergic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN ID KR MX SG US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN ID KR MX SG US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA